Helix Biopharma Corp. Expands Leadership Team With World-Class Oncology and Scientific Experts
Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are ...
Johnson & Johnson and 4 Other Biopharmaceutical Stocks That Might Be Ready to Break Out
Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...
Wells Fargo Reaffirms Their Buy Rating on Gilead Sciences (GILD)
Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00.
PharmiWeb1d
Industry Outlook 2025-2033: Healthcare Nanotechnology Market Size, Trends, and Growth Dynamics
The Latest research report offers an in-depth analysis of the Healthcare Nanotechnology Market, highlighting key trends in product segmentation, company dynamics, revenue streams, market share, recent ...
Fierce Pharma2d
Gilead sets aside $200M for potential settlement over HIV drug speaker program
Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
Gilead Sciences sets aside $200 million to resolve HIV drug probe
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...